Vaccinum influenzae pandemicae (H5N1) (vivum, attenuatum, intranasale)

Medicinal product name Pandemic influenza vaccine H5N1 AstraZeneca
Pharmaceutical form Nasal spray, suspension
Strength  
Information from the MAH on shortages Not notified
Legal status Rx Prescription (Pr.)
 Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website
ATC code J07BB03 Vaccines

Medicinal products (1)

Availability of medicinal product Wholesalers Package size, content Primary packaging Maximum admissible pharmacy price (€ incl. VAT) Product No. Labelling
 Not available (according to the information provided by wholesalers) currently no information on availability from any wholesaler N10
(1 UD/ml)
Glass applicator    EU/1/16/1089/001  Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website

Registration information

Marketing authorisation No. EU/1/16/1089/001
Date of authorisation May 20, 2016
MA valid until For unlimited time
Marketing authorisation holder, country AstraZeneca AB, Sweden